Aadi Bioscience Hits New 52-Week High of $4.13, Up 134.48%

Aadi Bioscience, Inc., a microcap company in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 4.13 on March 9, 2026. This achievement marks a notable increase from its 52-week low of USD 1.39, reflecting a remarkable one-year performance of 134.48%, significantly outperforming the S&P 500, which recorded a gain of 17.78% during the same period. With a market capitalization of USD 144 million, Aadi Bioscience operates in a competitive industry characterized by rapid innovation and development. The company's financial metrics indicate a challenging landscape, as it currently operates at a loss, with a negative return on equity of -9.94% and a debt-to-equity ratio of -1.03. Additionally, the company does not offer a dividend, and its price-to-book ratio stands at 0.91. This recent price movement underscores Aadi Bioscience's evolving market position within the pharmaceuticals and biotechnology industry, highlighting the dynamic nature of its stock performance.